Dynavax Technologies Corporation (NASDAQ:DVAX) shares gapped up before the market opened on Friday after Cantor Fitzgerald raised their price target on the stock from $24.00 to $25.00. The stock had previously closed at $18.35, but opened at $20.25. Cantor Fitzgerald currently has an overweight rating on the stock. Dynavax Technologies Corporation shares last traded at $20.25, with a volume of 9742917 shares changing hands.

The analysts wrote, “Launch in 1Q18. Dynavax anticipates launching the product in 1Q18 and previously noted drug supply of over 250,000 vials of product available by the time of launch, with an additional 750,000 vials worth of raw material. In 2H18, Dynavax expects its Dusseldorf plant to manufacture drug supply. We estimate the current supply will support commercialization for over two years, providing ample runway to produce additional supply.””

A number of other research analysts have also weighed in on the stock. Cowen and Company reissued a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research report on Friday, November 3rd. Royal Bank Of Canada reissued an “outperform” rating and set a $28.00 price target (up from $26.00) on shares of Dynavax Technologies Corporation in a research report on Monday, September 25th. ValuEngine raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. William Blair reissued an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Finally, Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $25.17.

A number of hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its position in Dynavax Technologies Corporation by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 456 shares during the period. Nationwide Fund Advisors raised its position in Dynavax Technologies Corporation by 2.5% in the second quarter. Nationwide Fund Advisors now owns 28,359 shares of the biopharmaceutical company’s stock worth $274,000 after acquiring an additional 692 shares during the period. Parametric Portfolio Associates LLC raised its position in Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 939 shares during the period. American International Group Inc. raised its position in Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 1,584 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC raised its position in Dynavax Technologies Corporation by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 1,700 shares during the period. 59.84% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. Dynavax Technologies Corporation had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The company’s revenue for the quarter was down 68.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. analysts anticipate that Dynavax Technologies Corporation will post -1.72 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Dynavax Technologies Corporation (DVAX) Shares Gap Up on Analyst Upgrade” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/11/11/dynavax-technologies-corporation-dvax-shares-gap-up-on-analyst-upgrade.html.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.